These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 15128409)
1. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. Thompson BE; Sachs BD; Kantak KM; Cherry JA Eur J Neurosci; 2004 May; 19(9):2561-8. PubMed ID: 15128409 [TBL] [Abstract][Full Text] [Related]
2. The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens. Janes AC; Kantak KM; Cherry JA Psychopharmacology (Berl); 2009 Oct; 206(2):177-85. PubMed ID: 19588125 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681 [TBL] [Abstract][Full Text] [Related]
4. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238 [TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Makhay MM; Houslay MD; O'Donnell JM Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620 [TBL] [Abstract][Full Text] [Related]
6. Effects of rolipram and diazepam on the adaptive changes induced by morphine withdrawal in the hypothalamic paraventricular nucleus. Núñez C; González-Cuello A; Sánchez L; Vargas ML; Milanés MV; Laorden ML Eur J Pharmacol; 2009 Oct; 620(1-3):1-8. PubMed ID: 19683523 [TBL] [Abstract][Full Text] [Related]
7. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor. Foissier L; Lonchampt M; Cogé F; Canet E J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536 [TBL] [Abstract][Full Text] [Related]
8. Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference. Bahi A; Kusnecov AW; Dreyer JL Behav Brain Res; 2008 Aug; 191(1):17-25. PubMed ID: 18436315 [TBL] [Abstract][Full Text] [Related]
9. Additive effects of intra-accumbens infusion of the cAMP-specific phosphodiesterase inhibitor, rolipram and cocaine on brain stimulation reward. Knapp CM; Lee K; Foye M; Ciraulo DA; Kornetsky C Life Sci; 2001 Aug; 69(14):1673-82. PubMed ID: 11589507 [TBL] [Abstract][Full Text] [Related]
10. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801 [TBL] [Abstract][Full Text] [Related]
11. Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor. Mamiya T; Noda Y; Ren X; Hamdy M; Furukawa S; Kameyama T; Yamada K; Nabeshima T Br J Pharmacol; 2001 Mar; 132(5):1111-7. PubMed ID: 11226142 [TBL] [Abstract][Full Text] [Related]
12. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors. Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323 [TBL] [Abstract][Full Text] [Related]
13. Altered Fos expression in neural pathways underlying cue-elicited drug seeking in the rat. Miller CA; Marshall JF Eur J Neurosci; 2005 Mar; 21(5):1385-93. PubMed ID: 15813948 [TBL] [Abstract][Full Text] [Related]
14. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. Harada D; Tsukumo Y; Takashima Y; Manabe H Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096 [TBL] [Abstract][Full Text] [Related]
15. The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice. Mueller EM; Hofmann SG; Cherry JA Neuropharmacology; 2010; 59(1-2):1-8. PubMed ID: 20362594 [TBL] [Abstract][Full Text] [Related]
16. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812 [TBL] [Abstract][Full Text] [Related]
17. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats. Sato T; Otaka M; Odashima M; Kato S; Jin M; Konishi N; Matsuhashi T; Watanabe S Biochem Biophys Res Commun; 2006 Jul; 346(1):339-44. PubMed ID: 16759642 [TBL] [Abstract][Full Text] [Related]
18. A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice. Hamdy MM; Mamiya T; Noda Y; Sayed M; Assi AA; Gomaa A; Yamada K; Nabeshima T Behav Brain Res; 2001 Jan; 118(1):85-93. PubMed ID: 11163637 [TBL] [Abstract][Full Text] [Related]
19. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice. Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015 [TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart. González-Cuello A; Sánchez L; Hernández J; Teresa Castells M; Victoria Milanés M; Laorden ML Eur J Pharmacol; 2007 Sep; 570(1-3):1-9. PubMed ID: 17601555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]